TRDA · NASDAQ · Biotechnology

Entrada Therapeutics (TRDA)

Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.

$6.47
vs last close−0.24 (−3.58%)